Mr. LaFrance became a Director of Vermillion and was elected Chairman of the Board in December 2013. He served as President and Chief Executive Officer from April to December 2014. He has almost thirty years of diagnostic industry experience. Most recently, Mr. LaFrance was head of digital pathology and acting CEO of Omnyx, LLC for GE Healthcare. Prior to that, he held a series of commercial, strategic marketing and business development leadership roles at Ventana Medical Systems (now Roche Tissue Diagnostics), including general manager of their North American and International commercial organizations. Prior to Ventana Mr. LaFrance served in leadership roles in strategic marketing and business development at Bayer Diagnostics. He was a member of the board at Mitomics, Inc. from 2010 to 2011. He earned a Bachelor of Arts degree in Economics from the University of Connecticut and an MBA from the University of Notre Dame.
For results that fall close to the cutoff ranges, physicians can now speak directly with the ASPiRA Labs’ Director, Dr. Fritsche. We hope this clinical discussion will help you better understand OVA1 scoring and assess the best treatment plan for your patients.